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Background: In patients with increased bleeding risk during dual antiplatelet therapy, the Biolimus 
A9-coated BioFreedom, a stainless steel drug-coated stent devoid of polymer, has shown superiority 
compared to a bare metal stent. The aim of this study was to investigate whether the polymer free 
biolimus A9-coated BioFreedom is non-inferior to a modern thin strut biodegradable polymer 
cobalt-chromium sirolimus-eluting Orsiro stent in an all-comers patient population treated with 
percutaneous coronary intervention. 
Methods: The multicenter SORT OUT IX trial (NCT02623140) randomly assigned all-comers 
patients to treatment with the BioFreedom drug-coated stent or the biodegradable polymer Orsiro 
stent in 4 Danish University Hospitals. The primary endpoint target lesion failure (TLF) is a 
composite of cardiac death, myocardial infarction (not related to other than index lesion) or target 
lesion revascularization within 12 months.  Clinically driven event detection based on Danish 
registries will be used and continue through five years. Assuming an event rate of 4.2% in each 
stent group, 1,563 patients in each treatment arm will provide 90% power to detect non-inferiority 
of the drug-coated BioFreedom stent with a non-inferiority margin of 2.1%.    
Results: 3150 patients have been randomized and enrolled in the study. 
Conclusion: The SORT OUT IX trial will determine whether the drug-coated BioFreedom stent is 
non-inferior to a modern biodegradable polymer Orsiro stent. 
  























In percutaneous coronary intervention with drug-eluting stent, the durable polymer 
used for first and second generation drug-eluting stents has been suspected as a potential trigger of 
vessel wall inflammation and late adverse outcomes.
1
 Hence newer generation drug-eluting stents 
with either biodegradable polymers or more biocompatible durable polymers, which have the 
potential to abolish these late events, have been developed.
2-5
 The target lesion failure rate for the 
biodegradable polymer sirolimus-eluting Orsiro stent was non-inferior to the gold standard 
everolimus-eluting stents in the BIOSCIENCE
3
 trial and non-inferior to the biodegradable polymer 
biolimus-eluting Nobori stent in the the SORT OUT VII trial.
6
 A polymer free and carrier free 
biolimus A9-coated BioFreedom stent has been developed, which is a highly lipophilic sirolimus 
analogue that transfers the biolimus A9 into the vessel wall over a period of 1 month
7
. Compared to 
the biodegradable polymer sirolimus-eluting Orsiro stent, the stents properties differ in 1) the 
biolimus A9 BioFreedom stent is polymer free and the sirolimus-eluting Orsiro stent has a silicon 
carbide coating and a circumferential polymer coating where the polymer degradation is taking 
place after 12-24 months, 2) the biolimus A9 BioFreedom stent has thicker stent struts (120 µm  
compared to the 60-80 µm for the sirolimus-eluting Orsiro stent, 3) faster drug release (1 month 
versus 12 weeks). The BioFreedom stent has shown superiority to a bare-metal stent in patients 
treated with only one month of dual antiplatelet therapy
7, 8
. However, it has not previously been 
studied if the BioFreedom stent have similar outcome results as a modern drug-eluting stent. In the 
SORT OUT IX trial, we have designed a registry-based randomized controlled non-inferiority trial 
comparing the polymer free biolimus A9-coated BioFreedom stent with the sirolimus-eluting Orsiro 





















Patients and study design 
  SORT OUT IX is a randomized, multicenter, single-blind, all-comers, two-arm, non-
inferiority trial comparing the polymer free biolimus A9-coated BioFreedom to the biodegradable 
polymer cobalt-chromium sirolimus-eluting Orsiro stent in patients treated with PCI. Patients were 
eligible, if they were at least 18 years old, had chronic stable coronary artery disease or acute 
coronary syndromes including ST-segment elevation myocardial infarction, and at least one 
coronary lesion with more than 50% diameter stenosis, requiring treatment with a drug-eluting 
stent. If multiple lesions were treated, the allocated study stent had to be used in all lesions. No 
restrictions were placed on number of treated lesions, number of treated vessels, or lesion length. 
Exclusion criteria were life expectancy of less than one year; an allergy to aspirin, clopidogrel, 
ticagrelor, sirolimus, or biolimus; participation in another randomized stent trial; or inability to 
provide written informed consent. The trial is registered with ClinicalTrials.gov, NCT02623140 and 
the study protocol was approved by the Danish Research Ethics Committee (S-20150132) and The 
Danish Data Protection Agency (15/47707). 
 
Informed consent and randomization 
  Between December 2015 and April 2017, a total of 3,150 patients were randomly 
assigned to treatment with polymer free biolimus A9-coated BioFreedom or biodegradable polymer 
cobalt-chromium sirolimus-eluting Orsiro stent at 4 Danish sites, 3 sites in Western Denmark 
(Odense University Hospital, Aarhus University Hospital and Aalborg University Hospital) and the 
Copenhagen University Hospital (Rigshospital). All patients signed the informed consent before 


















groups after diagnostic coronary angiography and before percutaneous coronary intervention. Block 
randomization by centre (permuted blocks of random sizes (2/4/6)) was used to assign patients in a 
1:1 ratio to receive the polymer free biolimus A9-coated BioFreedom stent (Biosensors, Morges, 
Switzerland) or the biodegradable polymer cobalt-chromium sirolimus-eluting Orsiro stent 
(Biotronik, Bülach, Switzerland). An independent organization computer-generated the allocation 
sequence, stratified by gender and presence of diabetes. Patients were assigned to treatment through 
a web based Trial Partner randomization system. While operators were not blinded, all individuals 
analyzing data were masked to treatment assignment. 
 
Study procedures and antithrombotic therapy 
The Orsiro stent was available in six diameters (2.25, 2.50, 2.75, 3.00, 3.50, and 4.00 
mm) and nine lengths (9, 13, 15, 18, 22, 26, 30, 35 and 40 mm). The BioFreedom stent was 
available in six diameters (2.25, 2.50, 2.75, 3.00, 3.50 and 4.00 mm) and eight lengths (8, 11, 14, 
18, 24, 28, 33 and 38mm). Stents were implanted according to standard techniques. Direct stenting 
without prior balloon dilation was allowed. Full lesion coverage was attempted by implanting one 
or more stents. Drug-eluting stents not specified by the random allocation scheme and bare metal 
stents were prohibited, unless the study stent could not be implanted. In such cases, other stents or 
balloon angioplasty alone were allowed. Before implantation, patients were treated with 
acetylsalicylic acid (loading dose of 300 mg) and loaded with either clopidogrel 600 mg, ticagrelor 
180 or prasugrel 60 mg. Combination of dual antiplatelet therapy was left to the discretion of the 
participating center whereas the duration of dual antiplatelet therapy was recommended for 6 
months in patients with stable angina pectoris and 12 months in patients with acute coronary 
syndromes. Unfractionated heparin dose (70-100 IU/kg) was administered before the procedure. 


















factors, baseline information, and procedure data are typed into the Western Denmark Heart 
Registry (WDHR)
9
, which contains detailed patient- and procedure-specific information on all 
coronary angiographies, coronary interventions and coronary bypass surgery performed at the three 
interventional and eight non-interventional cardiac centers in Western Denmark. For patients 
enrolled at Rigshospitalet (using another database system), the same variables were typed into a 
separate database and merged with data from the WDHR for patients enrolled at the other three 
centers. 
 
Outcome measures   
  The primary end point target lesion failure (TLF) is a composite of cardiac death, 
myocardial infarction (MI) (not related to other than index lesion) or clinically indicated target 
lesion revascularization (TLR) within 12 months. Individual components of the primary end point 
comprise the secondary end points: cardiac death; MI; clinically indicated TLR; all death (cardiac 
and non-cardiac) and target vessel revascularization; definite, probable, possible, and overall stent 
thrombosis according to the Academic Research Consortium (ARC) definition
10
; and a patient-
related composite end point (all death, all MI, or any revascularization). Clinical follow-up will be 
continued through 5 years. 
    
Definitions 
  Cardiac death: any death due to an evident cardiac cause, any death related to 
percutaneous coronary intervention, an unwitnessed death, or death from unknown causes.  
Myocardial infarction:  the universal definition used by the European Society of Cardiology, the 
American College of Cardiology, the American Heart Association, and the World Heart 
Federation.
11


















coronary intervention procedure. Myocardial infarction not related to other than index lesion: any 
myocardial infarction that is not clearly attributable to a non-target vessel. 
Stent thrombosis: definite, probable or possible stent thrombosis, according to the ARC
10
 definition. 
Target vessel revascularization: any repeat percutaneous coronary intervention or surgical bypass 
of any segment within the entire major coronary vessel that was proximal or distal to a target lesion, 
including upstream and downstream branches, and the target lesion itself.  
Target lesion revascularization: repeat revascularization caused by a more than 50% stenosis within 
the stent or within a 5 mm border proximal or distal to the stent. Target vessel and target lesion 
revascularization were clinically driven.  
 
Comorbidity: For all patients, we obtained data on all hospital diagnoses from the Danish National  
Registry of Patients covering all Danish hospitals from 1977 until the implantation date.
12
 We then 
computed  Charlson Comorbidity Index score, which covers 19 major disease categories, including 
diabetes mellitus, heart failure, cerebrovascular diseases, and cancer.
13
 
 Clinically driven event detection was used to avoid study-induced re-interventions (Figure 
1). Data on mortality, hospital admission, coronary angiography, repeat percutaneous coronary 
intervention, and coronary artery bypass surgery were obtained for all randomly allocated patients 
from the following national Danish administrative and healthcare registries: the Civil Registration 
System
14
; the Western Denmark Heart Registry
9, 15, 16
; and the Danish National Registry of 
Patients
12
, which maintains records on all hospitalizations in Denmark. 
  The Danish National Health Service provides universal tax-supported health care, 
guaranteeing residents free access to general practitioners and hospitals. The Danish Civil 
Registration System has kept electronic records on gender, birthdate, residence, emigration date, 
and vital status changes since 1968
14


















assigned at birth and used in all registries allows accurate record linkage. The Civil Registration 
System provided vital status data for our study participants and minimized loss to follow-up. The 
National Registry of Causes of Deaths and the Danish National Registry of Patients provided 
information on causes of death and diagnoses assigned by the treating physician during 
hospitalizations (coded according to the International Classification of Diseases, 10th revision 
[ICD-10]).
12 
  This methodology has been used in previous SORT OUT III-VII publications.
6, 17-20
 An 
independent event committee, masked to treatment group assignment during the adjudication 
process, reviewed all endpoints and source documents to adjudicate causes of death, reasons for 
hospital admission, and diagnosis of myocardial infarction. Two dedicated percutaneous coronary 
intervention operators at each participating centre reviewed independently cine films for the event 
committee to classify stent thrombosis, TLR and TVR (either with percutaneous coronary 
intervention or coronary artery bypass grafting).   
  
Statistical analysis 
  In analyses of every end point, follow-up will continue until the date of an end point 
event, death, emigration, or 12 months after stent implantation, whichever comes first. Survival 
curves will be constructed based on time to events, accounting for the competing risk of death. 
Hazard ratios will be computed using Cox proportional hazards regression analysis. Patients treated 
with the Orsiro stent will be used as the reference group for the overall analyses. Subgroup analyses 
(diabetes and acute coronary syndrome) will be performed. Hazard ratios will be calculated for TLF 
at 12-month follow-up for pre-specified patient subgroups (based on baseline demographic and 




















  The trial is powered for assessing non-inferiority of the Biolimus A9-coated 
BioFreedom stent to thin strut biodegradable polymer cobalt-chromium sirolimus-eluting Orsiro 
stent with respect to the primary endpoint at 12 months. An event rate of 4.2% is assumed in each 
stent group. With a sample size of 1,563 patients in each treatment arm, a two-group large-sample 
normal approximation test of proportions with a one-sided 0.050 significance level will have 90% 
power to detect non-inferiority with a predetermined non-inferiority margin of 2.1%. The sample of 
size 1,563 in each treatment arm assumes 0% lost-to-follow-up rate given the use of the Civil 
Registration System. A total number of 3,150 patients will be enrolled. 
  
 
Role of the funding source 
This study is investigator initiated and supported with an equal unrestricted grants 
from Biotronik, Bülach, Switzerland and Biosensors Interventional Technologies Pte Ltd., 
Singapore. These companies did not have a role in study design, data collection, data analysis, or 
interpretation of results. They also did not have access to the clinical trial database or an 




The SORT OUT IX trial will provide head-to-head randomized comparison of two 
modern DES with different designs: the Biolimus A9-coated BioFreedom, a stainless steel drug-
coated stent devoid of polymer, and the thin strut biodegradable polymer cobalt-chromium 


















polymer sirolimus-eluting Orsiro stent has a silicon carbide coating and a circumferential polymer 
coating where the polymer degradation is taking place, ultrathin cobalt-chromium stent struts and 
slower drug release. The sirolimus-eluting Orsiro stent has shown excellent efficacy and safety 
outcomes in several randomised clinical trials
3, 6, 21, 22
 and is a particularly suitable reference device 
for comparative stent studies.  
Among PCI treated patients with high risk for bleeding, the BioFreedom was superior 
to a similar bare metal stent (BMS), in patients treated with dual antiplatelet therapy for 1 month. 
Risks of myocardial infarction and target lesion revascularisatioin were significantly lower in the 
BioFreedom treated patients compared to patients treated with a BMS. In two third of the patient 
population age (>75 years) was one of the risk factors for high risk for bleeding.  The 1-year rate of 
definite stent thrombosis were higher than seen with modern thinner strut DES
3, 6, 21-23
and three-
fourth of the definite stent thrombosis occurred early when the patients were still on dual 
antiplatelet therapy without differences among the BioFreedom and the BMS treated patients. 
Safety and efficacy benefits of BioFreedom stent were maintained for 2 years.
8
   
The optimal duration of dual antiplatelet therapy (DAPT) in patients treated with 
complex lesions and/or high bleeding risk patients remains undetermined, and in addition, new stent 
designs using a bioabsorbable polymer might allow shorter duration of DAPT. In a recent meta-




Our study use patient-driven event detection based on Danish registries.
25
 This 
registry-based randomized clinical trial (RB-RCT) design has been used in all SORT OUT trials
6, 17-
20
, in the “Prevention of Contrast Induced Nephropathy with N-Acetyl Cysteine and/or Sodium 
Bicarbonate in Patients with ST-Segment Myocardial Infarction. A prospective, randomized, open-
labelled trial” (CINSTEMI)
26


















Myocardial Infarction” (TASTE) trial
27
, and has received substantial interest as a way of 
undertaking large-scale, independent clinical trials. The SORT- OUT trials are the first known 
Registry-based Randomized Clinical Trial, world wide and introduced, also this new concept in the 
Nordic countries.  
Advantages of this approach include a substantial reduction in the expense associated with a 
randomized trial because we are able to use the established registry infrastructure. Moreover, the 
study design provides data that are more comparable to real-life situations because of the absence of 
study-related intervention and participants will be exposed to the same clinical monitoring as 
nonstudy patients. Data on mortality (cardiac and noncardiac) are obtained from the Danish Civil 
Registration System
14
, hospital admission for myocardial infarction from the Danish National 
Registry of Patients
12
, and basic descriptive data, coronary angiography, repeat PCI, and coronary 
bypass surgery from the Western Denmark Heart Registry.
9
 Patient-driven event detection based on 
Danish registries will result in a nearly 100% follow up unless the patients have emigrated, which 
the CPR registry obtain information about with current residence of all Danish citizens. 
  In a population-based health care database like the Western Denmark Heart Registry, 
data are collected for quality-control and administrative purposes. This may reduce certain forms of 
bias, such as nonresponse bias, recall bias, and bias from loss to follow-up, which may influence 
prognostic estimates.
28
 Also, there are considerable costs associated with conducting an RCT. The 
Western Denmark Heart Registry contains detailed patient- and procedure-specific information on 
all coronary angiographies, coronary interventions and coronary bypass surgery performed at the 
three interventional centers in Western Denmark.  
  In Denmark, all citizens have a personal civil registration number assigned at birth or 
upon immigration.
14
 This unique personal identifier allows linkage of individual-level information 


















maintains records on date of birth, death, and current residence of all Danish citizens. The Danish 
National Registry of Patients
29
 contains information on all admissions and outpatient visits to the 52 
Danish hospitals. For each hospital admission, the registry records dates of admission and 
discharge, surgical procedures performed, and up to 20 diagnoses classified according to the 




  Like any conventional randomized trial, the SORT OUT trials use independent 
endpoint committee adjudication. Although the Danish health-care databases capture events of 
sufficient severity for patients to seek medical attention, these records might underestimate event 
rates compared with follow-up by dedicated trial staff.
30
 However, this situation should not bias 
differences detected between treatment groups, and the negligible loss to follow-up probably 
compensated for this potential limitation. 
 
Limitations     
  The primary endpoint is assessed after 1 year, and the TLF at 1 year may not predict 
the long term outcome with safety and efficacy after 5 years
31
. The clinical outcomes after 
implantation of drug-eluting stents have improved in recent years. Therefore we expect that the 
event rate in our study is representative of the real event rate among this patient population. Both 
study stents are available on the market, and even if one of the study stents will be replaced by a 
newer generation DES, both stent types have still been implanted in many patients, so the results 
with 1 year as well as long term follow-up will be relevant. All patients were recommended 6-12 
months of DAPT. Bleeding complications are not registered and may be underreported with registry 
information. Non-inferiority testing in essence flips the traditional null and alternative hypotheses. 


















This means that rather than assuming that there is no difference, the null hypothesis is that a 
difference exists and that the new treatment is inferior. As in a traditional trial, the two conclusions 
available from the statistical tests are: reject or failure to reject the null hypothesis. Rejecting the 
null hypothesis is making the statement that the new treatment is not worse than the old treatment.  
This implies that the new treatment is as good or even better that the old.   
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